Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

The LDRT deals with primary tumour in a 15 Gy of 5 fractions over five days, starting from Day 1 in the first cycle.

100 mg or 200 mg q3w until disease progression or intolerable toxicity;

240 mg q3w until disease progression or intolerable toxicity;

75 mg/m2 q3w for 4-6 cycles;

AUC = 5, q3w for 4-6 cycles;

100 mg/m2, d1, d2, d3, q3w for 4-6 cycles;